Department of Anaesthesia and Intensive Care, Gregorio Marañón's University Hospital, 28007 Madrid, Spain.
Department of Pharmacology, College of Medicine, Complutense University, 28040 Madrid, Spain.
Int J Mol Sci. 2024 May 11;25(10):5252. doi: 10.3390/ijms25105252.
Acute ischemic stroke (AIS) is a challenging disease, which needs urgent comprehensive management. Endovascular thrombectomy (EVT), alone or combined with iv thrombolysis, is currently the most effective therapy for patients with acute ischemic stroke (AIS). However, only a limited number of patients are eligible for this time-sensitive treatment. Even though there is still significant room for improvement in the management of this group of patients, up until now there have been no alternative therapies approved for use in clinical practice. However, there is still hope, as clinical research with novel emerging therapies is now generating promising results. These drugs happen to stop or palliate some of the underlying molecular mechanisms involved in cerebral ischemia and secondary brain damage. The aim of this review is to provide a deep understanding of these mechanisms and the pathogenesis of AIS. Later, we will discuss the potential therapies that have already demonstrated, in preclinical or clinical studies, to improve the outcomes of patients with AIS.
急性缺血性脑卒中(AIS)是一种具有挑战性的疾病,需要紧急的综合管理。血管内血栓切除术(EVT),单独或联合静脉溶栓,是目前治疗急性缺血性脑卒中(AIS)患者最有效的方法。然而,只有有限数量的患者符合这一时间敏感的治疗条件。尽管在这类患者的管理方面仍有很大的改进空间,但到目前为止,还没有批准用于临床实践的替代疗法。然而,仍有希望,因为目前正在进行的新型新兴疗法的临床研究正在取得有希望的结果。这些药物可以阻止或缓解脑缺血和继发性脑损伤中涉及的一些潜在分子机制。本综述的目的是深入了解这些机制和 AIS 的发病机制。之后,我们将讨论已经在临床前或临床研究中证明可以改善 AIS 患者预后的潜在疗法。